Evaluation of Immediate Preoperative Instillation (IPOI) of Mitomycin C Compared to Early Postoperative Instillation (IPOP) in Non-muscle Invasive Bladder Cancer

NCT ID: NCT02075060

Last Updated: 2017-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

54 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-28

Study Completion Date

2018-01-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this pilot study is to assess the efficacy and toxicity of immediate pre-operative instillation of mitomycin C compared to the standard early post-operative .

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Muscle-invasive Bladder Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

IPOI

One arm with pre-operative instillation of mitomycine 1h before TURB (IPOI : Instillation pré-opératoire immédiate),

Group Type EXPERIMENTAL

IPOI (pre-operative)

Intervention Type PROCEDURE

IPOP

One arm with early post-operative instillation of mitomycine within 24 hours (IPOP : Instillation Post Opératoire Précoce).

Group Type ACTIVE_COMPARATOR

IPOP (post-operative)

Intervention Type PROCEDURE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

IPOI (pre-operative)

Intervention Type PROCEDURE

IPOP (post-operative)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age \> 18 years,
* Primary or recurrent bladder tumor with endoscopic papillary aspect,
* One or two bladder tumors,
* Cytology before TURB showing no high-grade cells,
* Patients without tutorship or subordination (ou curatorship),
* Patients under the general social security system or qualifying through a third party,
* Informed consent signed by the patient after clear and fair information.

Exclusion Criteria

* Age \< 18 years,
* Allergy to mitomycin C,
* Traumatic stenting,
* Upper tract urothelial cancer,
* Urethral invasion,
* History of muscle invasive bladder cancer,
* Extensive tumor (3 cm or more),
* Any contraindication to TURB,
* Simultaneous participation in another clinical research study,
* Patients not insured by the social security or not qualifying through a third party,
* Patients with enhanced protection, namely pregnant or lactating women, persons deprived of their liberty by a judicial or administrative decision, people staying in a health or social institution, adults under legal protection, and finally patients in emergency situations,
* Pregnant or lactating females or women of childbearing potential not willing to use an adequate method of birth control for the duration of the study (i.e. hormonal / mechanical contraceptive : oral, injectable, transdermal, implantable, intrauterine or surgical device: tubal ligation, hysterectomy, total oophorectomy).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Poitiers University Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jacques IRANI, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Poitiers University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Bicêtre Hospital

Le Kremlin-Bicêtre, , France

Site Status RECRUITING

Poitiers University Hospital

Poitiers, , France

Site Status RECRUITING

Rouen University Hospital

Rouen, , France

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jacques IRANI, MD, PhD

Role: CONTACT

: +33 (0)5.49.44.44.77

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Geraldine PIGNOT, MD

Role: primary

+33-1 45 21 36 98

Jacques IRANI, MD, PhD

Role: primary

+33 (0)5.49.44.44.77

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IPOI vs IPOP

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Intravesical Adjuvant Electromotive Mitomycin-C
NCT01920269 COMPLETED PHASE2/PHASE3